<DOC>
	<DOC>NCT00236938</DOC>
	<brief_summary>This is a open-label, prospective study comparing intravenous (IV) iron supplementation to standard care in anemic patents undergoing peritoneal dialysis.</brief_summary>
	<brief_title>Efficacy and Safety of Venofer (Iron Sucrose Injection USP) in Patients Receiving Peritoneal Dialysis</brief_title>
	<detailed_description>This is an open-label, prospective study comparing IV iron supplementation to standard care in anemic patients undergoing peritoneal dialysis. After successfully completing a 6 month enrollment period, qualifying patients were randomized to receive 1000mg of IV iron over a four week period, or no iron supplementation. Erythropoietin regimen was to remain stable. Patients were followed to day 71 for safety and efficacy.</detailed_description>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric oxide, saccharated</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Hemoglobin &gt;= 9.5 and &lt;= 11.5 g/dL. Ferritin &lt;= 500 ng/ml. Serum Transferrin Saturation (TSAT) &lt;= 25%. Stable erythropoietin (EPO) Regimen for 8 weeks. No iron for last 4 weeks before randomization. Known Sensitivity to Iron Sucrose. Suffering concomitant severe diseases of the liver &amp; cardiovascular system. Pregnancy / Lactation. Inadequate dialysis. Current treatment for asthma. Significant blood loss. Probability of need for transfusion or transfusion within 1 week of enrollment. Anticipated major surgery. Hemochromatosis / hemosiderosis.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>iron</keyword>
	<keyword>peritoneal dialysis</keyword>
	<keyword>anemia</keyword>
</DOC>